Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

MorphoSys AG Investor Presentation 2009

Sep 11, 2009

291_ip_2009-09-11_6689dab0-a963-41b5-b939-b731a97cca56.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Sal. Oppenheim European Healthcare Investors Conference

August 31, 2009

Safe Harbour

This presentation includes forward forward-looking statements. looking

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic comp ,g y , g g etitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing.

These and other risks and uncertainties are detailed in the Company's Annual Report.

C
o
m
p
a
n
y		 A
i
d
d
i
b
d
t
t
"
n
n
e
p
e
n
e
n
a
n
o
y
c
o
m
p
a
n
y
F
k
f
S
k
E
h
T
D
A
X
t
t
"
r
a
n
r
o
c
c
a
n
g
e
e
c
u
x
–
S
3
7
5
l
t
4
i
t
i
D
U
K
U
"
e
m
p
o
y
e
e
s
a
s
e
s
n
,
,
P
i
l
i
p
e
n
e		 O
C
6
0
d
b
d
H
A
L
"
v
e
r
r
u
g
p
r
o
g
r
a
m
s
a
s
e
o
n
u
S
l
l
i
i
h
h
i
t
t
"
r
o
n
g
a
a
n
c
e
s
w
p
a
r
m
a
c
o
m
p
a
n
e
s
T
h
l
e
c
n
o
o
g
y		 C
f
L
d
i
i
t
H
A
L
l
t
"
e
a
n
g
p
r
o
p
r
e
a
r
y
u
p
a
o
r
m
,
S
&
d
i
d
t
t
t
t
t
t
"
r
o
n
g
u
n
s
p
u
e
p
a
e
n
e
s
a
e
i
i
F
l
n
a
n
c
a
s		 f
P
i
t
b
l
t
b
l
h
t
"
r
o
a
e
s
r
o
n
g
a
a
n
c
e
s
e
e
,

Building g yp a Strong Antibody Pipeline

Proprietary Programs – Goal: PoC in Humans

Current Product Pipeline: 68 Programs Ongoing

N
a
m
e		 P
t
a
r
n
e
r		 i
i
I
d
t
n
c
a
o
n		 i
D
s
c
o
v
e
r
y		 i
i
P
l
r
e
c
n
c		 P
h
1
a
s
e		 P
h
2
a
s
e		 P
h
3
a
s
e		 M
k
t
a
r
e
G
t
b
a
n
e
n
e
r
u
m
a		 R
h
o
c
e		 A
D
B
H
Q
8
8
0		 N
t
i
o
v
a
r
s		 C
a
n
c
e
r
C
O
8
8
8
N
T		 C
t
e
n
o
c
o
r		 /
I
l
m
m
u
n
o
o
g
y
C
a
n
c
e
r
d.
n.		 C
t
e
n
o
c
o
r		 I
f
l
t
i
n
a
m
m
a
o
n		 P
d
6
2
t
a
r
n
e
r
e		 P
r
o
g
r
a
m
s
d.
n.		 N
i
t
o
v
a
r
s		 d.
n.
3
1
P
t
d
a
r
n
e
r
e
P
r
o
g
r
a
m
s		 V
i
a
r
o
u
s		 V
i
*
a
r
o
u
s
2
5
P
t
d
a
r
n
e
r
e
P
r
o
g
r
a
m
s		 V
i
a
r
o
u
s		 *
V
i
a
r
o
u
s
M
O
R
1
0
3		 - R
A
O
M
R
2
0
2		 - C
a
n
c
e
r
M
O
R
2
0
3		 - C
a
n
c
e
r		 5
P
i
t
r
o
p
r
e
a
r
y		 P
r
o
g
r
a
m
s
M
O
R
2
0
5		 - C
a
n
c
e
r
M
O
R
1
0
4		 - I
f
l
i
t
n
a
m
m
a
o
n
d
d.
n
n.		 M
h
S
/
o
r
p
o
s
y
N
t
i
o
a
r
s
v		 d
d.
n
n.		 1
P
P
D
D
P
r
r
e
e-
e
e
v
v.
r		 o
g
r
a
m

* Includes cancer, inflammatory, autoimmune, infectious, musculoskeletal & central nervous system diseases

Partnered HuCAL Antibodies in Clinical Trials

Partnered Business: Projected HuCAL Drugs on the Market

Source: MorphoSys internal statistics & Tufts Centre for the Study of Drug Development

MOR103 Phase I Study

Primary Objectives: Safety & Tolerability

Single i v. . infusion at doses ranging up to 3 mg/kg were generally safe and well tolerated

Secondary Objectives Objectives: PK and Immunogenicity

  • Pharmacokinetics were generally consistent between subjects and throughout the dose range studied
  • No anti-MOR103 IgG antibodies were observed in doses up to 3 mg/kg
  • Chang g es in general IgA, IgG, and IgM concentrations, y, if any, were similar in all groups, including the placebo

Phase1b/2a Trial Design

  • More than 130 Rheumatoid Arthritis patients
  • Multiple centers in several European countries to ensure robust i ipatient recruitment

MOR202Proprietary Cancer Program

  • MOR202, a fully human HuCAL antibody, targeting CD38, a 45 kDa ectoenzyme heavily over-exp p ressed in 95% of multiple myeloma and some leukemia cell lines
  • Function: Induces cell-killing by ADCC, CDC & apoptosis
  • Primary indication: Multiple myeloma indication:
  • Commercial opportunity
  • 10 % of hematological cancers / 1% of all cancers / 2% of cancer deaths
  • No curative therapies
  • Median survival 24 – 30 months, all patients eventually relapse

Outlook 2009:

  • Further evaluation in animal models of multiple myeloma
  • Start of non non-clinical safety study to support clinical testing clinical
  • Start of preclinical efficacy studies in second indication
  • Production and release of mAb material for animal safety testing and in preparation for phase 1/2a clinical testing in 2010

Clinical Pipeline

Number of Partnered and Proprietary Clinical Compounds at Year-End

Clinical Antibody Pipeline is a Key Value Driver

AbD Serotec: The Business

CUSTOM

  • Greater footprint in diagnostic markets

  • Syner gies with Rx segment

  • Depends on public and private R&D budgets

  • Large customer base, tool Leverage own sales y g to establish brand

  • Fewer customers, larger orders

  • force

AbD Serotec: Solid Progress

Growth

  • AbD Serotec H1 2009 revenues: +8%
  • Market growing at 3 – 5%

P fit ro

  • AbD Serotec now solidly profitable
  • Investing now for future growth

Diagnostics

  • First HuCAL antibody in a diagnostic kit ( (Phadia)
  • Multiple diagnostic projects ongoing

Management

  • Dieter Feger, SVP – new head of unit
  • 20 years in sales & marketing at Abbott Diagnostics marketing DiagnosticsMorphoSys AG – Company Update – September 2009 Page 14

MorphoSys Group Financial Guidance 2009

I
E
U
R
i
l
l
i
n
m
o
n
s		 E
*
2
0
0
9		 A
2
0
0
8
T
l
G
R
t
o
a
r
o
u
p
e
v
e
n
u
e
s		 5
8
0
8
–		 1.
6
7
G
O
i
P
f
i
t
t
r
o
p
p
e
r
a
n
g
r
o
u		 8
1
1
–		 1
6
4

► I f t t l i t R&D i t t t EUR 18 Increase o total proprietary investment to – 20 million (2008: EUR 7.7 million)

MorphoSys Group Outlook

  • Aiming for 10%–20% annual revenue growth
  • M i t i fit bilit hil t th i i li aintain profit ability, while strengthening pipeline

Shareholder Structure and Key Financials

Shareholder Structure

Key Financials (H1 2009)

25.

N
i
l
i
i
l
f
f
i
l
i
l
t
t
e
a
r
n
g
c
n
c
a
p
r
o
o
o
c
o
n
c
e
p
n
m
p
e
p
r
o
g
r
a
m
s
u		 C
l
i
i
l
P
C
n
c
a
o
S
M
h
o
r
p
o
y
s		 O
1
0
3
M
R		 R
A
R
h
o
c
e		 G
b
t
a
n
e
n
e
r
m
a
u		 A
A
l
l
h
h
i
i
's
z
z
e
e
m
m
e
e
r
r
s
D
i
s
e
a
s
e
N
t
i
o
v
a
r
s		 Q
B
H
8
8
0		 O
l
n
c
o
o
g
y
C
t
e
n
o
c
o
r		 C
O
N
T
8
8
8		 O
l
n
c
o
o
g
y
I
f
l
i
t
n
a
m
m
a
o
n
N
t
i
o
v
a
r
s		 U
d
n
n
a
m
e		 d.
n

New deals (alliances partnerships in -licensing ) (alliances, partnerships, …

Thank You.

www.morphosys.com

Dr. Simon Moroney

Chief Executive Officer

Phone +49 (0)89 / 899 27-311 ( ) ( ) Fax +49 (0)89 / 899 27-5311 Email [email protected]

Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR

Phone +49 (0)89 / 899 27-122 Fax +49 (0)89 / 899 27-5122 Email [email protected]

More from MorphoSys AG

AGM Information 2024
Aug 27
Delisting Announcement 2024
Aug 5
AGM Information 2024
Jul 19
AGM Information 2024
Jul 19
Declaration of Voting Results & Voting Rights Announcements 2024
Jul 18
Delisting Announcement 2024
Jul 12
Legal Proceedings Report 2024
Jul 12
Report Publication Announcement 2024
Jul 5
Major Shareholding Notification 2024
Jul 2
Declaration of Voting Results & Voting Rights Announcements 2024
Jun 21
View all filings →